Del Mar Pharmaceuticals Inc. (DMPI) to Present at the Small-Cap Stars Spring Conference 2015 at Convene in Times Square New York on June 10

NEW YORK, June 4, 2015 (GLOBE NEWSWIRE) -- Del Mar Pharmaceuticals Inc. (OTCMKTS:DMPI), a biopharmaceutical development and exploration company, will be presenting at the Small-Cap Stars Spring Conference 2015 at Convene in Times Square New York on Wednesday, June 10. The event is a gathering of the brightest emerging growth small-cap and pre-IPO companies to present and network with an exclusive group of top-level institutional investors.

Del Mar Pharmaceuticals Inc.: Jeffrey A. Bacha, Co-Founder and CEO

Time: 1:30 – 1:50 pm (ET)

Equities.com designed this full-day event dedicated to creating unparalleled discovery and exclusive networking sessions. For more details on the conference, please visit http://www.equitiesevents.com.

Registration for the conference is still available but space is limited. We encourage you to register by clicking this link (http://bit.ly/1Q7aMRx) as soon as possible to ensure your participation. Presenters and attendees can schedule private one-on-one meetings to maximize their networking opportunities.

Participation in this exclusive conference is for institutional investors interested in small-cap and pre-IPO opportunities. In attendance will be: Hedge Funds, Family Offices, Portfolio Managers, Investment Banks and Venture Capitalists.

To learn more about how you can participate and to stay up-to-date on all conference-related news, please visit www.equitiesevents.com.

To register for the conference, please visit: http://bit.ly/1Q7aMRx

About Del Mar Pharmaceuticals Inc.

Del Mar Pharmaceuticals, Inc. was founded to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The Company's lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients.

About Equities.com, Inc.

Equities.com is an online financial news organization and social community for self-directed investors, public and private companies, market experts, and professional service providers across the global capital markets. The Equities.com Issuer Dashboard is an ideal SaaS platform to effectively manage corporate communication and investor awareness campaigns, engage with market intermediaries and financial advisors, and research industry peers. Registered members can leverage our market-leading commentary and content curation, as well as our proprietary research tools, such as our robust do-it-yourself Equities Valuation Analysis (E.V.A.) research reports. Go to http://www.equities.com/community/register to become a member.

CONTACT: Danielle Blackwell
         Conference and Event Director
         Office: 310-822-5500 ext 135
         danielle@equities.com

Released June 4, 2015